relapses in ovarian cancer patients (Kozyreva et al. 1994 ).
In addition. higher Cath D concentrations have been found in cytosolic extracts from omental metastases than from primary ovarian tumours. as reported by us and other authors (Scambia et al, 1991 : Henzen-Logmans et al. 1994 . Moreover. the possible association of Cath D with ovarian cancer patient prognosis has been only preliminarily investigated (Scambia et al. 1994) .
The aim of this study was to analyse the clinical significance of Cath D content detennined by an immunoradiometric assay in a large series of primary untreated ovarian tumours from 162 patients. The correlation between Cath D and biological parameters. such as oestrogen receptor (ER) . progesterone receptor (PR) and epidermal growth factor receptor (EGFR). were also investigated.
In addition. the specific contribution of tumour epithelial and adjacent stromal cells to total Cath D content was studied by immunohistochemistry on a subset of 86 cases. and the possible relationship between immunohistochemical and immunoradiometric results was also analysed.
MATERIALS AND METHODS
One hundred and sixty-two previously untreated patients with histologically confirmed diagnosis of ovarian carcinoma were admitted to the study. Seventy-two cases were from our previous study (Scambia et al. 1994) . None of the patients had received chemotherapy previously. All patients were staged according to the FIGO (International Federation of Gynecology and Obstetrics. Tumour tissue processing At the time of surgery. the tumour specimens were dissected and divided into txo parts: one part %vas frozen in liquid nitrogen and stored at -80CC to be used for receptor detection and the other part was fixed for 24 h in neutral-buffered formalin. After fixation. blocks were routinely paraffin embedded.
Preparation of cytosol and membrane fractions Briefly. tumour specimens were finely minced and homogenized in five volumes of ice-cold buffer [25 mm Tris. 1.5 mms EDTA. 5 mm sodium azide. 0.1%7 monothioglvcerol and 20%7 glycerol (TENMG) . pH = 7.4] by applying several intermittent bursts of an Ultra-Turrax homogenizer. The crude homogenate A as centrifuged at 7000 g for 20 min at 0 C. The supernatants were then centrifuged at 105 000 g for 75 min at 0C. obtaining the cvtosolic fraction and the membrane pellet (Scambia et al. 19951. Immunoradiometric assay Cath D concentration was assayed in the cvtosolic fraction using a solid-phase two-site immunoradiometric assay (CIS Bioindustries. Gift-Sur-Yvette. France). Protein concentration was measured by the Bradford method (Bradford. 1976). using bovine All medians and life-tables were calculated using the product-limit estimate, and the curves were examined by means of the log-rank test (Mantel, 1966 
RESULTS

Immunoradiometric analysis
The distribution of Cath D levels in 162 primary ovarian tumours. including previously described tumours (Scambia et al. 1994) . is shown in Figure 1 Figure 3A shows the overall survival curves in relation to Cath D cytosolic status, defined using a cut-off of 21 pmol mg-' protein.
corresponding to the median value. The 5-year overall survival was 57% and 55% in Cath D-positive and Cath D-negative patients respectively (P = 0.69). Similar results were obtained at any cut-off tested (data not shown).
As far as time to progression is concemed, no significant difference in the survival rate of patients with high or low Cath D content was observed. as shown in Figure 3B (P = 0.56). Cox's Hazard regression analysing Cath D as a continuous variable gave similar results (data not shown).
Survival analysis was also conducted on the subgroup of 86 patients in whom Cath D was analysed by immunohistochemistry.
The 5-year time-to-progression rate was 23% for epithelial Cath D-positive compared with 38% for epithelial Cath D-negative cases (P = 0.91) and 30% for stromal Cath D-positive compared with 37% for stromal Cath D-negative cases (P = 0.67). The 5-year overall survival was not significantly different between Cath Dpositive and Cath D-negative cases for both epithelial (P = 0.94) and stromal (P = 0.67) components. (Ferrandina et al. 1997 Cahepsin D and ovarian cancer prognosis 1651 by means of proteolytic enzymes represents a key step during local metastatic process. Further studies are needed to gain a deeper insight into the molecular patterns regulating key steps in ovarian tumour cell invasiveness and spread.
In addition, it is possible that regulation of the net protease activity balance, involving cathepsin proenzymes, inhibitors and the urokinase-type plasminogen activator system (uPA), which interact with each other, is different in ovarian than in breast cancer cells. Rochefort et al (1987) reported that Cath D secretion can be induced by oestradiol in human breast cancer cells. Tamoxifen has also been demonstrated to induce, through its oestrogenic activity, an increase in Cath D mRNA levels in breast cancer cells in vitro (Johnson et al, 1989; Chalbos et al, 1993) and in vivo . In our series, higher Cath D levels were found in ER-positive tumours, in accordance with results by Galtier-Dereure et al (1992) , who demonstrted that secretion of pro-Cath D in BG-1 ovarian tumour cells is oestrogen responsive. However, considering Cath D as a marker of oestrogen responsiveness is debatable, as even the role of oestrogen receptors in ovarian tumours is still controversial.
In conclusion, Cath D assessment seems to have little meaning, if any, in characterizing ovarian cancer patient prognosis. However, it has to be taken into account that Cath D might act as a trigger of potentially important proteolytic cascades, thus leading to the activation of proenzyrnes, such as Cath B and uPA, the latter having been recently reported to be associated with an unfavourable prognosis in ovarian cancer patients (Kozyreva et al, 1994; Kuhn et al, 1994) .
Therefore, the simultaneous assessment of a panel of functionally related proteases and their inhibitors could be helpful in clarifying the biological and possibly the clinical role of these factors in ovarian cancer.
